Clinical Pharmacy

CP-188

INTRA-ABDOMINAL INFECTIONS IN DIGESTIVE SURGERY WARDS: IS EMPIRIC ANTIBIOTIC TREATMENT IN ACCORDANCE WITH LOCAL MICROBIOLOGICAL ECOLOGY?

CP-187

KNOWLEDGE OF HIV INFECTED PATIENTS ON ANTIRETROVIRAL THERAPY AND HIV INFECTION

CP-186

CAN THE ANTIRETROVIRAL THERAPY EFFECTIVENESS BE CONNECTED WITH TREATMENT SIMPLIFICATION?

CP-185

THE IMPORTANCE OF ASSESSING ASYMPTOMATIC BACTERIURIA IN HOSPITALISED PATIENTS

CP-183

OVARIAN STIMULATION IN ASSISTED REPRODUCTION TECHNIQUES

CP-181

PROFILE OF USE OF A MUCOSITIS COMPOUNDED SUSPENSION IN PATIENTS AFFECTED WITH MUCOSITIS

CP-180

QUALITY OF ARTIFICIAL NUTRITION SUPPORT IN AN INTENSIVE CARE UNIT

CP-179

PATIENTS EXCEEDING DOXORUBICIN RECOMMENDED CUMULATIVE DOSE

CP-176

THE HOSPITAL PHARMACIST AS A MEMBER OF A MULTIDISCIPLINARY TEAM IN PERIOPERATIVE MANAGEMENT OF CHRONIC MEDICATION

CP-174

THERAPY EDUCATION PROGRAMME IN HEART FAILURE – 3 YEAR EVALUATION

CP-172

TYROSINE KINASE INHIBITORS IN THE TREATMENT OF RENAL CELL CARCINOMA IN ROUTINE CLINICAL PRACTICE

CP-171

USE OF ERIBULIN IN METASTASIC BREAST CANCER

CP-169

EFFECTIVENESS OF BIOSIMILAR FILGRASTIM VS ORIGINAL GRANULOCYTE-COLONY STIMULATING FACTOR (G-CSF) IN FEBRILE NEUTROPENIA PREVENTION IN BREAST CANCER PATIENTS RECEIVING DOCETAXEL/DOXORUBICIN/CYCLOPHOSPHAMIDE (TAC)

CP-168

OBESE PATIENTS: ARE DOSE ADJUSTMENTS FOR TREATMENT OF COMORBIDITIES USED?

CP-167

EFFECTIVENESS OF THE NEW DIRECT-ACTING ANTIVIRAL AGENTS IN PATIENTS WITH CHRONIC HEPATITIS C GENOTYPE 4

Pages